re: Ann: Year Ended 2013 - Results Release Pr... Upfront I have been a long time holder of MCP, so my comments are meant to be objective.
JID - I would argue that cash flows are not "solid". Rather their yoy operating cash flow decreased by about 10%. The only improvement in cash flow was due to their share issue.
The $ value of sales has increased, yes, but that is a meaningless measure of their profitability. For example, 2nd half 2012/13 sales increased from $132.3mio to $146mio, yet normalised NPAT for the half decreased from $6.7mio to $5.6mio.
As I said above, I have been a long time holder of MCP. But, I have substantially reduced my holding - both before and after their results were released.
For anyone wanting a "punt" on MCP I would strongly recommend that before doing so you run a set of comparative/trend numbers (sales, prices, ratios, etc) for the last 3 years or so.
IT AINT PRETTY!!
- Forums
- ASX - By Stock
- MCP
- Ann: Year Ended 2013 - Results Release Presentati
MCP
mcpherson's limited
Add to My Watchlist
4.76%
!
22.0¢

Ann: Year Ended 2013 - Results Release Presentati, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
22.0¢ |
Change
0.010(4.76%) |
Mkt cap ! $31.66M |
Open | High | Low | Value | Volume |
22.0¢ | 22.0¢ | 22.0¢ | $1.001K | 4.548K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 156774 | 21.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 135334 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 156774 | 0.210 |
3 | 137858 | 0.205 |
11 | 168742 | 0.200 |
2 | 15391 | 0.195 |
1 | 2634 | 0.190 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 135334 | 7 |
0.225 | 298 | 1 |
0.235 | 5000 | 1 |
0.240 | 55000 | 2 |
0.250 | 10000 | 1 |
Last trade - 10.00am 26/06/2025 (20 minute delay) ? |
Featured News
MCP (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online